Background: The vascular endothelial growth factor (VEGF) mediates vasculogenesis and angiogenesisthrough promoting endothelial cell growth, migration and mitosis, and has involvement in cancer pathogenesis,progression and metastasis. However, the prognostic value of VEGF in patients with prostate cancer remainscontroversial.
Objectives: The aim of our study was to evaluate the prognostic value of VEGF in prostate cancer,and summarise the results of related research on VEGF.
Methods: In accordance with an established searchstrategy, 11 studies with 1,529 patients were included in our meta-analysis. The correlation of VEGF-expressionwith overall survival and progression-free survival was evaluated by hazard ratio, either given or calculated.
Results: The studies were categorized by introduction of the author, demographic data in each study, prostatecancer-relatived information, VEGF cut-off value, VEGF subtype, methods of hazard ratio (HR) estimationand its 95% confidence interval (CI). High VEGF-expression in prostate cancer is a poor prognostic factor withstatistical significance for OS (HR=2.32, 95%CI: 1.40–3.24). However, high VEGF-expression showed no effecton poor PFS (HR=1.30, 95%CI: 0.88–1.72). Using Begg’s, Egger’s test and funnel plots, we confirmed lack ofpublication bias in our analysis.
Conclusion: VEGF might be regarded as a prognostic maker for prostate cancer,as supported by our meta-analysis. To achieve a more definitive conclusion enabling the clinical use of VEGF inprostate cancer, we need more high-quality interventional original studies following agreed research approachesor standards.